Results 101 to 110 of about 103,862 (301)

Poly(ADP-ribose) polymerase-1 activity facilitates the dissociation of nuclear proteins from platinum-modified DNA [PDF]

, 2008
The affinity of the poly(ADP-ribose) polymerase-1 (PARP-1) for platinum-damaged DNA was first discovered during photo-cross-linking experiments using the photoactive compound Pt-BP6 [J. Am. Chem. Soc.
Guggenheim, Evan R., Lippard, Stephen J., Movassaghi, Mohammad, Ondrus, Alison E.   +3 more
core   +2 more sources

Understanding and Overcoming Antibody‐Drug Conjugate Resistance: Biological Mechanisms and Emerging Analytical Frameworks in Breast Cancer

Advanced Science, EarlyView.
Antibody–drug conjugates (ADCs) transform breast cancer therapy, yet resistance limits their durability. Emerging evidence reveals that ADC failure is not solely tumor‐intrinsic but shaped by dynamic tumor–microenvironment interactions that alter drug delivery, processing, and response.
Minji Seo, Jangsoon Lee, Naoto T. Ueno
wiley   +1 more source

Advances in the use of PARP inhibitor therapy for breast cancer

Drugs in Context, 2018
Poly-ADP-ribose polymerase 1 (PARP-1) and PARP-2 are DNA damage sensors that are most active during S-phase of the cell cycle and that have wider-reaching roles in DNA repair than originally described.
Kelly E McCann, Sara A Hurvitz
doaj   +1 more source

Halofuginone is a Molecular Glue Degrader of Integrin β4

Advanced Science, EarlyView.
Integrin β4 overexpression is linked to aggressive tumors and poor prognosis, but targeted therapies are lacking. We identified halofuginone (HF) as a molecular glue degrader that promotes integrin β4 degradation via the CRL4BWDR18 E3 ligase. HF suppresses tumor progression in vitro and in vivo, offering a new strategy for targeting oncogenic ...
Wei Gong, Di Yang, Junrui Tian, Yufei Chai, Tiantian Yu, Qingnan Wu, Yan Wang, Weimin Zhang, Qimin Zhan   +8 more
wiley   +1 more source

PARP Inhibitors for Cancer Therapy

Cell, 2017
Rucaparib is an inhibitor of nuclear poly (ADP-ribose) polymerases (inhibition of PARP-1 > PARP-2 > PARP-3), following a similar drug, Olaparib. It disrupts DNA repair and replication pathways (and possibly transcription), leading to selective killing of cancer cells with BRCA1/2 mutations.
Ken Y, Lin, W Lee, Kraus
openaire   +2 more sources

SLC2A3‐Mediated Lactate Metabolism Promotes Lung Cancer Bone Metastasis by Modulating P53 Lactylation and Immune Evasion

Advanced Science, EarlyView.
SLC2A3 derived lactate promotes metastasis through p53 lactylation at K120 and osteoclast differentiation. Pharmacological inhibition of SLC2A3 upregulates PD‐1 expression on CD8+ T cells via lactate induced p53 lactylation, which modulates immune evasion. ABSTRACT Bone metastasis is a devastating consequence of lung cancer.
Yi Ding, Yuying Tian, Wenjie Ren, Xianglin Hu, Mengjuan Li, Bei Liu, Chen chen, Yunhan Lu, Lei Li, Wangjun Yan, Kun Li   +10 more
wiley   +1 more source

Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma.

PLoS ONE, 2015
Ewing's sarcoma is a malignant pediatric bone tumor with a poor prognosis for patients with metastatic or recurrent disease. Ewing's sarcoma cells are acutely hypersensitive to poly (ADP-ribose) polymerase (PARP) inhibition and this is being evaluated in
Sonja J Gill, Jon Travers, Irina Pshenichnaya, Fiona A Kogera, Syd Barthorpe, Tatiana Mironenko, Laura Richardson, Cyril H Benes, Michael R Stratton, Ultan McDermott, Stephen P Jackson, Mathew J Garnett   +11 more
doaj   +1 more source

Poli(ADP-ribóz) polimeráz gátló vegyületek hatásmechanizmusának vizsgálata állatkísérletes és rheologiai modelleken = Evaluation of mechanism of action of poly(ADP-ribose) polymerase inhibitor compounds in animal and in rheological models [PDF]

, 2009
Kutatásaink során kísérletes szívelégtelenség modellekben vizsgálatuk a poli(ADP-ribóz) polimeráz (PARP) gátlók hatását. Vizsgálatainkkal igazoltuk, hogy PARP-gátlók mérséklik a postinfarctusos remodelinget és védenek a szívelégtelenség kialakulásával ...
Alexy, Tamás, Deres, Péter, Horváth, Beáta, Koltai, Katalin, Kovács, Krisztina, Késmárky, Gábor, Márton, Zsolt, Pálfi, Anita, Szabados, Eszter, Sümegi, Balázs, Tóth, Ambrus, Tóth, Kálmán   +11 more
core  

Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy [PDF]

, 2014
BRCA1, a key factor in homologous recombination repair may also regulate base excision repair (BER). Targeting BRCA1-BER deficient cells by blockade of ATM and DNA-PKcs could be a promising strategy in breast cancer.
Abdel-Fatah, TMA, Agarwal, D, Albarakati, N, Alsubhi, N, Arora, A, Ball, G, Caldas, C, Chan, S, Doherty, R, Ellis, IO, Green, A, Madhusudan, S, Moseley, P, Perry, C, Rakha, EA, Russell, R, Seedhouse, C   +16 more
core   +1 more source

DMAP1 Deficiency Suppresses Lung Cancer Progression by Destabilizing Replication Fork and Activating IFN Signaling‐Mediated Anti‐tumor Immunity

Advanced Science, EarlyView.
Lung cancer remains the leading cause of cancer‐related death. We investigated the role of the epigenetic regulator DMAP1 in NSCLC and found that its loss induces replication stress and DNA damage. This in turn activates type I IFN signaling via the cGAS–STING pathway and transcriptional ISG de‐repression, enhancing anti‐tumor immune responses ...
Kan Huang, Xi Dai, Shuaihu Li, Yingxue Chen, Yaxin Yu, Lin Wang, Kun Liu, Shuhan Lyu, Chongyang Li, Yihua Sun, Fei Li   +10 more
wiley   +1 more source